The BD MAX RVP is an RT- PCR assay, designed to detect and differentiate the mRNA of SARS-CoV-2, flu A, flu B and RSV using an automated workflow of the BD MAX System, within two hours
Becton, Dickinson and Company (BD) has rolled out the BD MAX Respiratory Viral Panel (RVP), its new combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV).
The molecular diagnostics company secured the CE mark approval for its combination test, under the EU in-vitro diagnostics (IVD) directive 98/79/EC.
Its BD MAX Respiratory Viral Panel uses a single nasal swab or a single nasopharyngeal swab sample to identify if a patient is infected with Covid-19 or the flu or RSV.
BD said that the combined test will eliminate the need for multiple tests or doctor visits and help clinicians rapidly employ appropriate treatment plans.
Also, the co-testing approach would help increase the testing capacity during the busy flu season and speeds the time to diagnosis, said the company.
BD Molecular Diagnostics vice president Nikos Pavlidis said: “SARS-Cov-2, influenza and RSV are a triple threat, as patient symptoms and clinical presentation can be nearly identical.
“A combined testing panel is key to enabling clinicians to quickly and efficiently diagnose, differentiate and treat patients to help manage the spread of the infections.”
The BD MAX RVP is an RT- PCR assay, designed to detect and differentiate the mRNA of SARS-CoV-2, flu A, flu B and RSV, all within two hours.
It runs on the easy-to-use and automated workflow of the BD MAX System.
The BD MAX System is a molecular diagnostic platform capable of analysing hundreds of samples over 24 hours.
The company is currently commercialising BD MAX RVP in countries that consider the CE mark.
It intends to pursue Emergency Use Authorization (EUA) from the US Food and Drug Administration in a few weeks.
Last month, BD agreed to acquire pharmacy automation solutions provider Parata Systems from private equity firm Frazier Healthcare Partners for a total consideration of $1.525bn.